RecruitingPhase 2

The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Lead sponsor

Mayo Clinic

Asset

Avexitide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06967558

Org study ID24-007677

Timeline

Milestones

Study first posted2025-05-13actual

Study start2025-11-01actual

Last update posted2025-12-15actual

Primary completion2027-10-30estimated

Study completion2028-03-31estimated

Assets

Investigational agents

Avexitide

Who can enroll

Minimum age25 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•People with stable weight and no history of diabetes.

•Fasting glucose < 126 mg/dL

•2hr glucose after 75g OGTT < 200 mg/dL

Exclusion criteria

•Age < 25 or > 70 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).

•HbA1c > 6.5%

•Use of any glucose-lowering agents including metformin or sulfonylureas.

•For female subjects: positive pregnancy test at the time of enrollment or study

•History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.

•Active systemic illness or malignancy.

•Symptomatic macrovascular or microvascular disease.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.